Compounds > dopamine glucuronide

Page last updated: 2024-11-10

dopamine glucuronide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dopamine glucuronide: metabolite of dopamine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	3082490
CHEBI ID	88776
SCHEMBL ID	21594822
MeSH ID	M0113929

Synonyms (17)

Synonym
beta-d-glucopyranosiduronic acid, 4-(2-aminoethyl)-2-hydroxyphenyl
dopamine glucuronide
(2s,3s,4s,5r,6s)-6-[4-(2-aminoethyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
38632-24-5
b-d-glucopyranosiduronic acid,4-(2-aminoethyl)-2-hydroxyphenyl
CHEBI:88776
4-(2-aminoethyl)-2-hydroxyphenyl beta-d-glucopyranosiduronate
4-(2-aminoethyl)-2-hydroxyphenyl beta-delta-glucopyranosiduronic acid
4-(2-aminoethyl)-2-hydroxyphenyl beta-delta-glucopyranosiduronate
dopamine-4-o-glucuronide
4-(2-aminoethyl)-2-hydroxyphenyl beta-d-glucopyranosiduronic acid
SCHEMBL21594822
Q27160736
4-(2-aminoethyl)-2-hydroxyphenyl hexopyranosiduronic acid
DTXSID70959475
dopamine 4-?-d-glucuronide
dopamine 4- beta -d-glucuronide

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
glucosiduronic acid	Any substance produced by linking glucuronic acid to another substance via a glycosidic bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (66.67)	18.7374
1990's	1 (16.67)	18.2507
2000's	1 (16.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.25 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.20 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
homovanillic acid Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.	1.96	1	0	guaiacols; monocarboxylic acid	human metabolite; mouse metabolite
deferiprone Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.	1.99	1	0	4-pyridones	iron chelator; protective agent
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	1.96	1	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
dopamine 3-o-sulfate dopamine 3-O-sulfate: end product of L-Dopa metabolism in Parkinson patients; see also record for dopamine 4-O-sulfate. dopamine 3-O-sulfate : An aryl sulfate that is dopamine in which the phenolic hydrogen at position 3 has been replaced by a sulfo group.	2.37	2	0	aryl sulfate; phenols; primary amino compound; zwitterion	human blood serum metabolite; human urinary metabolite
noradrenaline sulfate [no description available]	2.66	3	0	catecholamine
dopamine 4-o-sulfate dopamine 4-O-sulfate: possible precursor of free norepinephrin; see also record for dopamine 3-O-sulfate. dopamine 4-O-sulfate : An aryl sulfate that is dopamine in which the phenolic hydrogen at position 4 has been replaced by a sulfo group.	2.37	2	0	aryl sulfate; phenols; primary amino compound; zwitterion	human blood serum metabolite; human urinary metabolite
5-hydroxytryptamine o-sulfate 5-hydroxytryptamine O-sulfate: found in superfusates of rat spinal cord; RN given refers to hydrogen sulfate ester	1.96	1	0
epinephrine sulfate [no description available]	2.37	2	0	catecholamine
carbidopa Carbidopa: An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself.. carbidopa : The hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.	1.96	1	0